Navigation Links
MedQuist Evaluating Whether a Sale of the Company is in the Best Interests of the Company and its Shareholders

MT. LAUREL, N.J., Nov. 2 /PRNewswire-FirstCall/ -- MedQuist Inc. (Pink Sheets: MEDQ) announces that its Board of Directors, in connection with its previously-disclosed review of strategic alternatives for the Company, is evaluating whether a sale of the Company is in the best interests of the Company and its shareholders, in light of the announcement earlier today by Koninklijke Philips Electronics N.V. ("Philips") of its decision to proceed with the sale of its 70% ownership interest in the Company if a satisfactory price and other acceptable terms can be realized. There is no assurance that any sale transaction will occur as a result of the evaluation.

About MedQuist:

MedQuist is a leading provider of clinical documentation workflow solutions in support of the electronic health record. MedQuist provides electronic medical transcription, health information and document management products and services, including digital dictation, speech recognition, Web- based transcription, electronic signature, medical coding, mobile dictation devices, and outsourcing services.

"Safe Harbor" Statement under the U.S. Private Securities Litigation Reform Act of 1995: Statements in this press release regarding MedQuist's business which are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation that the Company's evaluation of whether a sale of the Company is in the best interest of the Company and its shareholders may not result in a sale of the Company, and that any potential sale transaction reviewed by the Company may not be attractive to shareholders and may not result in enhanced shareholder value. Actual outcomes and results may differ materially from what is expressed or forecasted in forward- looking statements. As a result, forward-looking statements speak only as of the date they were made, and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE MedQuist Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Evaluating The Risks and Benefits of Hormone Therapy
2. Evaluating The Risk Factors Of Osteoporosis
3. Evaluating The Benefits Of A Low – carb Diet
4. US Doctors re-evaluating Conjoined Twin Surgery
5. VA Should Revise Its Methods for Evaluating PTSD in Ex-military Personnel
6. Experts Question Whether Expert Patient Programmes Cut Healthcare Use
7. US Court Asked to Decide Whether Childhood Vaccines can Cause Autism
8. Researchers To Test Whether ADHD Medication Helps Young Adults While Driving
9. Medicis Pharmaceutical company enters pediatric market
10. Problems Of a Growing Company
11. Teenagers Take More Risk-Taking Behaviors In The Company Of Same Sex Friends
Post Your Comments:
(Date:11/27/2015)... VVA (PRWEB) , ... November 27, 2015 , ... ... motto of progress through sharing, the 2016 Building Better Radiology Marketing ... The conference will begin on Sunday, March 6, 2016, at Caesars Palace in ...
(Date:11/27/2015)... ... 2015 , ... The moment you stop improving is the ... the needs of advisers and clients but going above and beyond to find ... service. However, there's always room for improvement, which is why the entire Consulting ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... the largest, most successful and prominent nonprofit healthcare organizations in the country. They ... involvement with various organizations, and helped advance the healthcare industry as a whole ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
(Date:11/26/2015)... ON (PRWEB) , ... November 26, 2015 , ... ... of a real-time eReferral system for diagnostic imaging in the Waterloo region. Using ... BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) without ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... -- Lannett Company, Inc. (NYSE: LCI ) today ... Kremers Urban Pharmaceuticals Inc. (KU), the U.S. specialty ... S.A. (Euronext: UCB). --> ... UCB for total consideration of approximately US$1.23 billion, ... capital adjustment, a deduction of certain reimbursable amounts ...
(Date:11/26/2015)... 2015 Un nuevo enfoque combina ... el cáncer avanzado.   --> Un ... de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... --> Clinical Cancer Research . --> ...
(Date:11/26/2015)... 2015 --> --> ... to find optimal contrast weighting of MRI for patients ... signed a research agreement with SyntheticMR in order to use ... it is possible to generate multiple contrast images from a ... has left, thus making it possible to both fine tune ...
Breaking Medicine Technology: